NCT01276639 is a Phase 3 clinical trial of CP-690,550 in Psoriasis, sponsored by Pfizer.

Who is sponsoring NCT01276639?

NCT01276639 is sponsored by Pfizer.

What drugs are being tested in NCT01276639?

Interventions in NCT01276639: CP-690,550, CP-690,550, Placebo/CP-690,550, Placebo/CP-690,550.

Is NCT01276639 still recruiting?

NCT01276639 is currently completed. Last updated 18 September 2014.

Are results published for NCT01276639?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2014-09-18 · How we verify

NCT01276639

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy And Safety Of 2 Oral Doses Of CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis

Completed Phase 3 Results posted Last updated 18 September 2014

What this trial tests

Phase 3 trial testing CP-690,550 in Psoriasis in 901 participants. Completed in 1 April 2013.

Timeline

1 March 2011

Primary endpoint
1 April 2013

1 April 2013

Quick facts

Lead sponsor	Pfizer
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	901
Start date	1 March 2011
Primary completion	1 April 2013
Estimated completion	1 April 2013
Sites	74 locations across United States, Canada, Colombia, Germany, Hungary, Japan, Mexico, Poland

Drugs / interventions tested

CP-690,550 — full drug profile →
CP-690,550 — full drug profile →
Placebo/CP-690,550 — full drug profile →
Placebo/CP-690,550 — full drug profile →

Conditions studied

Psoriasis — all drugs for Psoriasis →

Sponsor

Pfizer — full company profile →

Who can join

18 and older, any sex, with Psoriasis. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' at Week 16
Time frame: Week 16
The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded
Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 16
Time frame: Week 16
The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of body surface area (BSA)" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttock

Sponsor's own description

The main objective of this study is to compare the effects of CP-690,550 with the effects of placebo in patients being treated for moderate to severe chronic plaque psoriasis. This one-year study will also evaluate the safety and tolerability of CP-690,550 versus placebo.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials.
Papp KA, Menter MA, Abe M, Elewski B, et al · · 2015 · cited 231× · PMID 26149717 · DOI 10.1111/bjd.14018
Targeting the Janus Kinase Family in Autoimmune Skin Diseases.
Howell MD, Kuo FI, Smith PA. · · 2019 · cited 180× · PMID 31649667 · DOI 10.3389/fimmu.2019.02342
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E, Chaimani A, Garcia-Doval I, Do G, et al · · 2017 · cited 106× · PMID 29271481 · DOI 10.1002/14651858.cd011535.pub2
Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases.
Szilveszter KP, Németh T, Mócsai A. · · 2019 · cited 102× · PMID 31447854 · DOI 10.3389/fimmu.2019.01862
JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis.
Hsu L, Armstrong AW. · · 2014 · cited 88× · PMID 24883332 · DOI 10.1155/2014/283617
Systemic Treatment of Psoriasis with JAK Inhibitors: A Review.
Kvist-Hansen A, Hansen PR, Skov L. · · 2020 · cited 84× · PMID 31893355 · DOI 10.1007/s13555-019-00347-w
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E, Chaimani A, Afach S, Doney L, et al · · 2020 · cited 78× · PMID 31917873 · DOI 10.1002/14651858.cd011535.pub3
The arrival of JAK inhibitors: advancing the treatment of immune and hematologic disorders.
Furumoto Y, Gadina M. · · 2013 · cited 73× · PMID 23743669 · DOI 10.1007/s40259-013-0040-7

Verify or expand the search:

Other trials of CP-690,550

Trials testing the same drug.

NCT02831855 — Methotrexate Withdrawal Study of Tofacitinib Modified Release Formulation in Subjects With Rheumatoid Arthritis · Phase 4 · completed
NCT01470612 — Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis · Phase 3 · completed
NCT01458574 — A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis · Phase 3 · completed
NCT00678561 — Topical CP-690,550 For Chronic Plaque Psoriasis · Phase 2 · completed
NCT01743677 — CP-690,550 Thorough QTc Study · Phase 1 · completed

Other recruiting trials for Psoriasis

Currently open trials in the same condition.

NCT07471048 — A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoria · NA · recruiting
NCT07449234 — A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis · recruiting
NCT07234838 — Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO) · recruiting
NCT07194200 — Safety and Efficacy of Lactobacillus Plantarum for Psoriasis: A Randomized Double-Blind Placebo-Controlled Trial · Phase 2 · recruiting
NCT07250997 — PALLAS Laser for Skin Diseases · NA · recruiting

Other Pfizer trials

Trials by the same sponsor.

NCT04982848 — Korea Post Marketing Surveillance (PMS) Study of Talzenna® · not yet recruiting
NCT06873191 — A Study to Learn More About Tukysa Once it is Out in the Korean Market · not yet recruiting
NCT07497854 — A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea · not yet recruiting
NCT06507904 — A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Anta · Phase 1 · not yet recruiting
NCT06864585 — A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01276639 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pfizer
Last refreshed: 18 September 2014

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01276639.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing